MHRA approves adapted Covid vaccine

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Pfizer/BioNTech’s adapted COVID-19 vaccine (Comirnaty) that targets Omicron XBB.1.5.

The vaccine was approved after it was found to meet the UK regulator's standards of safety, quality and effectiveness.

The adapted vaccine works in the same way as the original vaccine by causing the immune system (the body’s natural defences) to produce antibodies and blood cells that work against the virus, so giving protection against COVID-19.

The vaccine has been approved for those aged 6 months and over.

Image by Memed_Nurrohmad from Pixabay

Event Diary

This story was first published in digitalhealth.net

Supplier Profiles

CDC success at Victoria Infirmary, Northwich creates ideal model for future patient pathway reforms

Northwich’s Victoria Infirmary (VIN) Community Diagnostic Centre (CDC) has enabled more patients

Gain valuable insight with Adveco for gas to electric decarbonisation projects

Adveco, the commercial hot water specialist, announces the launch of live metering of domestic ho